This regulatory update reviews a completed trial comparing two robotic clip devices for safety and efficacy in prostate, kidney and urothelial cancers. Publication context is February 19, 2026. The ClinicalTrials.gov record NCT07413120 shows the study evaluating VasoClip and WeckClip in robotic urologic surgery. Sponsors listed are Incheon St.Mary’s Hospital and the Korea Health Industry Development Institute. The record identifies the eligible conditions and the devices under evaluation. No trial results are provided in this summary; the record confirms completion and the comparator devices involved.
What changed in device evaluation for robotic urologic surgery?
The study compared two vascular clipping devices used during robotic surgery. The intervention listed include VasoClip and WeckClip. The record shows three cancer categories as potential targets for the procedure: prostate cancer, kidney cancers and urothelial cancer. The format of the trial suggests a direct device to device comparison with emphasis on safety and efficacy endpoints. Specific results are not included in the source text, so readers should refer to the clinical trial page for detailed findings. The sponsor institutions are named as Incheon St. Marys Hospital in Korea and the Korea Health Industry Development Institute. This arrangement indicates a government and hospital based regulatory research effort spanning multiple cancer types. The completion status indicates the study concluded and may provide data for future regulatory assessment and device selection in robotic surgery.
What is the clinical trial context and scope?
The trial is positioned in the setting of robotic urologic surgery where hemostasis and tissue handling influence outcomes. The devices under study are clip based and designed to secure vascular structures during procedures. By comparing VasoClip against WeckClip within an identical surgical workflow, investigators intend to isolate device related performance differences. The inclusion of prostate, kidney and urothelial cancers broadens the potential clinical applications. Regulators and clinicians will look for consistency of performance across cancer types and procedural steps. The trial is listed as completed in the source text, and the publication of detailed results will affect practice guidance and device selection in the robotic arena.
What are the regulatory implications?
From a regulatory perspective the trial supports real world data on device performance in a high complexity surgery setting. The MDR style language would require a clear statement of intended use, device classification and the risk management documentation. The comparison between two devices represents a direct head to head evaluation. Information on safety signals, device related adverse events and performance endpoints would influence physician choice and post market surveillance. The sponsor disclosures and clinical trial status are relevant for regulatory filings and potential future submissions. The public record at ClinicalTrials.gov serves as a primary source for device regulators seeking to verify study design, endpoints and completion status.
What safety considerations are anticipated or observed?
Given the focus on safety and efficacy, readers should expect a detailed analysis of device related risks such as vascular injury clip failure and interaction with robotic instruments. The trial design aims to quantify safety in relation to operative time blood loss and postoperative recovery, though the source text does not provide numerical results. Clinicians will want guidance on device handling, deployment technique and failure modes. Regulators may require comprehensive risk mitigation data including device material compatibility and sterilization validation. The approach followed by the sponsors aligns with regulatory expectations for comparative device assessment in a surgical field where patient outcomes are highly sensitive to clip performance.
What is the current status and next steps?
The source notes completion of the trial and lists the sponsor organizations. The next steps typically include the publication of full results and analysis, potential regulatory submissions or updates to device labeling and training materials, and possibly post market surveillance plans. Readers should monitor the ClinicalTrials.gov page referenced in this article for updates and the sponsor institutions press or regulatory filings for interpretation of the findings. The data may influence device selection in robotic urologic procedures across the cancer spectrum noted in the trial.
FAQ
- 1. What is being compared? A head to head evaluation of two clipping devices used in robotic urologic surgery.
- 2. Which cancers are included? Prostate cancer, kidney cancers and urothelial cancer are listed in the source text.
- 3. Who sponsors the study? Incheon St. Marys Hospital and the Korea Health Industry Development Institute.
- 4. Where can I find more information? The clinical trial page on ClinicalTrials.gov is the primary source provided.
- 5. Does this trial report results? The source text notes completion but does not include results.
Conclusion
In summary, this completed trial offers a direct comparison of two robotic clipping devices in a mixed cancer setting. The information may inform device selection and regulatory considerations in robotic urologic surgery. Clinicians and regulators should await the full results to understand the balance of efficacy and safety between VasoClip and WeckClip. Stakeholders should track the official trial page for updates and for data that could influence labeling and practice guidelines.
Disclaimer: This article is intended for professional readers and is not legal advice. It provides a regulatory style summary based on the listed source text. For formal guidance please consult regulatory counsel and the official marketing authorization documents.
https://clinicaltrials.gov/study/NCT07413120?term=medical+device